Patent Cliff Hiring Radar
Drugs losing exclusivity in the next 24 months, ranked by hiring velocity at the affected companies. The thesis: pharma companies hire ahead of patent cliffs to launch lifecycle-extension follow-ons, defend share, and transition reps to other portfolio drugs. A “Hot” company about to lose exclusivity is the most actionable career signal we surface.
100 branded drugs with LOE dates within 24 months · sorted by hiring velocity then by months-to-cliff
Cliff within 12 months
Most-time-sensitive — companies under active hiring pressure tend to be here.
these symptoms associated with hay fever, other upper respiratory allergies, the common cold: runny nose itchy +3
including term, preterm neonates, a source of calories +4
bacteria
bacteria
bacteria
Substance P/Neurokinin-1 Receptor Antagonist [EPC]
12 to 24 months out
Earlier signal — lifecycle-extension hiring usually kicks in here.
Methodology: LOE (loss of exclusivity) dates come from FDA Orange Book patent + exclusivity records, taking the earlier of the two. Hiring velocity is computed from CrawlRun deltas over the last 30 days (jobs created − jobs removed) at the company level. “Hot” ≥ +20, “Growing” ≥ +5, “Stable” ±5, “Cooling” ≤ −5, “Contracting” ≤ −20. Patent cliffs are not financial advice; companies adjust hiring for many reasons beyond exclusivity loss.